Lorbrena/ Lorviqua ( lorlatinib) 100 mg №30 in tab, generic
Product Catalog
Cart
Cart is empty
LorviqvaLorlatinib100 mgthirtyТабБангладешь Lorviqua Indications \r\n It is indicated as first-line therapy for the treatment of adult patients with ALK-positive advanced non-small cell lung cancer (NSCLC). \r\n It is indicated as monotherapy for the treatment of adult patients with ALK-positive advanced non-small cell lung cancer (NSCLC) whose disease has progressed after receiving the following agents: alectinib or ceritinib as first-line therapy with ALK tyrosine kinase inhibitors (TKIs); or crizotinib and at least one other ALK TKI.
Lorbrena/ Lorviqua ( lorlatinib) 100 mg №30 in tab, generic
It is indicated as first-line therapy for the treatment of adult patients with ALK-positive advanced non-small cell lung cancer (NSCLC).
It is indicated as monotherapy for the treatment of adult patients with ALK-positive advanced non-small cell lung cancer (NSCLC) whose disease has progressed after receiving the following agents: alectinib or ceritinib as first-line therapy with ALK tyrosine kinase inhibitors (TKIs); or crizotinib and at least one other ALK TKI.
